vTv Therapeutics (VTVT) Stock: Buy, Sell, or Hold?
VTVT - vTv Therapeutics Inc. Class A Common Stock
$30.57
-1.28 (-4.02%)
▼
5d:
+1.19%
30d:
-8.47%
90d:
-11.49%
HOLD
LOW Confidence
Analysis Updated: Oct 2, 2026 12:00 AM ET
Earnings: Nov 05, 2026
Get Alerted When VTVT Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: VTVT shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
📊 HOLD: VTVT shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
In-depth Analysis How we analyze
Valuation Analysis: VTVT is currently trading at $30.57, which is considered oversold relative to its 30-day fair value range of $30.63 to $32.94.
Technical Outlook: Technically, VTVT is in a downtrend. The price is currently testing key support at $29.68. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 4.0% recently.
Market Sentiment: VTVT scores 60/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $54.71 (+79.0%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, VTVT is in a downtrend. The price is currently testing key support at $29.68. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 4.0% recently.
Market Sentiment: VTVT scores 60/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $54.71 (+79.0%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$30.63 -
$32.94
Company Quality Score
57/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
89.5%
All Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-4.0%)
- BULLISH: Trading 79.0% below Wall St target ($54.71)
- CAUTION: Bottoming setup, but lagging the sector by 23% over 20 days — wait for relative strength
Trading Range Analysis
30-Day Trading Range
$30.63 -
$32.94
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$29.68
Resistance Level
$32.38
Current Trend
Downtrend
Technical data as of
Oct 2, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-6.50
Wall Street Target
$54.71
(+79.0%)
Profit Margin
-12.9%
Share & Embed Analysis
Last updated: October 03, 2026 10:39 PM ET
Data refreshes hourly during market hours. Next update: 11:39 PM
Data refreshes hourly during market hours. Next update: 11:39 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is VTVT showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ONC
BeiGene, Ltd. |
STRONG BUY
24 analysts |
$433 | 56 HOLD |
|
CRSP
Crispr Therapeutics AG |
BUY
28 analysts |
$88 | 54 HOLD |
|
INSM
Insmed Inc |
STRONG BUY
21 analysts |
$199 | 49 HOLD |
|
CYTK
Cytokinetics Inc |
STRONG BUY
21 analysts |
$110 | 63 BUY |
|
CRNX
Crinetics Pharmaceutical… |
STRONG BUY
17 analysts |
$86 | 46 HOLD |
